

# William Hogan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5191791/publications.pdf>

Version: 2024-02-01

338  
papers

5,616  
citations

94269

37  
h-index

110170

64  
g-index

339  
all docs

339  
docs citations

339  
times ranked

6604  
citing authors

#	ARTICLE	IF	CITATIONS
1	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
2	Outcome of Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 358-367.	2.0	245
3	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>Leukemia</i> , 2013, 27, 1322-1327.	3.3	212
4	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
5	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. <i>Bone Marrow Transplantation</i> , 2013, 48, 557-561.	1.3	158
6	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	0.8	146
7	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
8	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012, 118, 1585-1592.	2.0	106
9	The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 605-616.	2.0	103
10	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. <i>Leukemia and Lymphoma</i> , 2010, 51, 2181-2187.	0.6	102
11	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100
12	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1131-1135.	1.4	90
13	Risk Factors and Outcome of Pulmonary Complications After Autologous Hematopoietic Stem Cell Transplant. <i>Chest</i> , 2012, 141, 442-450.	0.4	87
14	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521.	2.0	83
15	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
16	Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 87-93.	2.0	76
17	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
18	Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 305-309.	1.3	67

#	ARTICLE	IF	CITATIONS
19	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 1003-1008.	1.3	66
20	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	2.5	63
21	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182.	1.3	61
22	Second auto-SCT for treatment of relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 568-573.	1.3	59
23	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Blood Research</i> , 2014, 49, 100.	0.5	56
24	Momelotinib treatmentâ€emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015, 169, 77-80.	1.2	56
25	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
26	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1189-1211.	1.4	55
27	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1617-1624.	1.4	53
28	Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. <i>Blood Cancer Journal</i> , 2017, 7, e607-e607.	2.8	52
29	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455.	1.3	51
30	Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1690-1695.	2.0	51
31	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29.	2.8	49
32	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
33	Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. <i>JAMA Oncology</i> , 2017, 3, 1253.	3.4	47
34	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
35	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 204-211.	1.3	41
36	Vancomycinâ€eresistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920.	0.7	40

#	ARTICLE	IF	CITATIONS
37	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. <i>American Journal of Hematology</i> , 2018, 93, 649-654.	2.0	40
38	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015, 29, 741-744.	3.3	38
39	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512.	2.8	38
40	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	2.0	37
41	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
42	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
43	Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside. <i>Mayo Clinic Proceedings</i> , 2002, 77, 760-762.	1.4	32
44	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484.	2.0	31
45	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132.	1.3	30
46	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40.	1.3	30
47	Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2264-2269.	2.0	29
48	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29
49	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 49.	2.8	28
50	Emergencies in Hematology and Oncology. <i>Mayo Clinic Proceedings</i> , 2017, 92, 609-641.	1.4	27
51	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
52	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
53	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439.	2.0	26
54	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26

#	ARTICLE	IF	CITATIONS
55	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
56	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1710-1716.	2.0	24
57	Efficacy of biological agents in the treatment of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018, 183, 520-524.	1.2	24
58	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e497.	3.1	24
59	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with $\alpha$ -1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	2.5	24
60	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.	2.5	23
61	Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1804-1812.	2.0	22
62	Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant. <i>Journal of Clinical Apheresis</i> , 2015, 30, 147-153.	0.7	22
63	Use of cyclosporine in hematopoietic cell transplantation. <i>Transplantation Proceedings</i> , 2004, 36, S367-S371.	0.3	21
64	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. <i>Clinical Transplantation</i> , 2014, 28, 1084-1091.	0.8	21
65	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
66	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1906-1913.	2.0	21
67	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1753-1768.	1.4	21
68	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 121.	2.8	21
69	Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. <i>Leukemia and Lymphoma</i> , 2008, 49, 1724-1730.	0.6	20
70	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 546-549.	0.2	20
71	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015, 29, 498-500.	3.3	20
72	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374.	1.4	20

#	ARTICLE	IF	CITATIONS
73	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
74	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 579-583.	2.0	19
75	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18.	2.8	19
76	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	2.0	19
77	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460.	2.0	19
78	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	0.6	19
79	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018, 71, 60-62.	0.4	18
80	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. <i>American Journal of Hematology</i> , 2017, 92, 866-871.	2.0	17
81	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600.	0.6	17
82	Primary Myelodysplastic Syndromes. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1623-1638.	1.4	16
83	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
84	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
85	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
86	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	3.3	16
87	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011, 118, 3849-3849.	0.6	16
88	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
89	Emergencies in haematology: tumour lysis syndrome. <i>British Journal of Haematology</i> , 2020, 188, 494-500.	1.2	15
90	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15

#	ARTICLE	IF	CITATIONS
91	Prognostic Relevance of Monosomy at the 13q14 Locus Detected by Fluorescence In Situ Hybridization in B-Cell Chronic Lymphocytic Leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1999, 110, 77-81.	1.0	14
92	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2013, 3, e122-e122.	2.8	14
93	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2016, 18, 216-226.	0.7	14
94	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016, 56, 518-527.	0.8	14
95	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
96	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
97	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 36.	2.8	14
98	Overview of the progress on haploidentical hematopoietic transplantation. <i>World Journal of Transplantation</i> , 2016, 6, 665.	0.6	14
99	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.	1.3	13
100	Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. <i>American Journal of Medicine</i> , 2021, 134, e31-e35.	0.6	13
101	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
102	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010, 116, 3554-3554.	0.6	13
103	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	13
104	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2588-2597.	0.6	12
105	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1467-1474.	1.4	12
106	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.2	11
107	Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. <i>European Journal of Haematology</i> , 2017, 99, 275-282.	1.1	11
108	Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763). <i>Transfusion</i> , 2019, 59, 2840-2848.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 165.e1-165.e11.	0.6	11
110	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 63.	2.8	11
111	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. <i>Chest</i> , 2021, 159, 2325-2333.	0.4	11
112	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.2	10
113	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	1.7	10
114	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
115	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	2.0	10
116	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	0.6	10
117	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E433-E436.	2.0	10
118	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
119	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2737-2739.	0.6	9
120	Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 146-154.	1.3	9
121	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
122	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
123	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
124	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
125	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 990-999.	0.6	9
126	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. <i>JAMA Dermatology</i> , 2020, 156, 631.	2.0	9



#	ARTICLE	IF	CITATIONS
127	<i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021, 195, 413-416.	1.2	9
128	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013, 122, 2151-2151.	0.6	9
129	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	2.5	9
130	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015, 6, 45.	0.7	8
131	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , 2016, 50, 112-115.	0.4	8
132	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. <i>Blood Cancer Journal</i> , 2017, 7, 647.	2.8	8
133	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 155-161.	1.3	8
134	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159.	2.0	8
135	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	1.3	8
136	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68.	2.8	8
137	Response to erythropoiesisâ€stimulating agents in patients with WHOâ€defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). <i>British Journal of Haematology</i> , 2020, 189, e104-e108.	1.2	8
138	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€ A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 1-9.	1.2	8
139	Fulminant Hepatic Failure Secondary to Adenovirus Following Fludarabine-Based Chemotherapy for Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 1145-1150.	0.6	7
140	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 80.	6.9	7
141	Prognostic impact of combined NPM1+/FLT3â€ genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015, 39, 1207-1213.	0.4	7
142	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1714-1715.	0.6	7
143	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
144	The association of de novo anti-HLA-DPB1 donor-specific antibody formation and primary graft failure after allogeneic hematopoietic cell transplantation. <i>Human Immunology</i> , 2018, 79, 861-864.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
146	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
147	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 764-767.	0.6	7
148	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA±venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021, 96, E108-E111.	2.0	7
149	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021, 11, 122.	2.8	7
150	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	7
151	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	7
152	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e39-e41.	0.2	6
153	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. <i>Human Immunology</i> , 2018, 79, 532-536.	1.2	6
154	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1542-1550.	1.4	6
155	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1232-1239.	2.0	6
156	A population-based study of chronic eosinophilic leukemia not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257.	2.0	6
157	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 46.	2.8	6
158	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, E327-E330.	2.0	6
159	Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease: a real-world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432.	1.2	6
160	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
161	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	1.2	6
162	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. <i>Blood Cancer Journal</i> , 2021, 11, 170.	2.8	6

#	ARTICLE	IF	CITATIONS
163	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. Blood, 2006, 108, 116-116.	0.6	6
164	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. Blood, 2010, 116, 3572-3572.	0.6	6
165	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. Blood, 2012, 120, 3555-3555.	0.6	6
166	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	1.3	6
167	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	2.0	5
168	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology, 2019, 98, 331-337.	0.8	5
169	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	1.3	5
170	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	1.3	5
171	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. Blood, 2016, 128, 2799-2799.	0.6	5
172	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. Blood, 2010, 116, 2253-2253.	0.6	5
173	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	0.6	5
174	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer Journal, 2022, 12, 7.	2.8	5
175	Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Advances, 2022, 6, 5227-5231.	2.5	5
176	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	1.3	4
177	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. British Journal of Haematology, 2018, 182, 141-145.	1.2	4
178	Differential expression of interferon- $\alpha$ -induced genes and other tissue- $\alpha$ -based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. Clinical and Experimental Dermatology, 2019, 44, e81-e88.	0.6	4
179	The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients. International Journal of Hematology, 2020, 111, 293-302.	0.7	4
180	Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<sc>P</sc>hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	2.0	4

#	ARTICLE	IF	CITATIONS
181	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4
182	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	2.8	4
183	The Increasing Relevance of Copper Deficiency in Hematological Practice.. <i>Blood</i> , 2005, 106, 1679-1679.	0.6	4
184	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016, 128, 1123-1123.	0.6	4
185	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with 7+3. <i>Blood Cancer Journal</i> , 2022, 12, 55.	2.8	4
186	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
187	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627.	2.0	3
188	Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogeneic Stem Cell Transplant Recipient. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2018, 2, 387-391.	1.2	3
189	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3 mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404.	2.0	3
190	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019, 60, 2483-2487.	0.6	3
191	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 960-962.	1.3	3
192	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021, 11, 65.	2.8	3
193	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
194	A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. <i>Blood</i> , 2004, 104, 1505-1505.	0.6	3
195	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. <i>Blood</i> , 2015, 126, 1050-1050.	0.6	3
196	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5234-5234.	0.6	3
197	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016, 128, 2798-2798.	0.6	3
198	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016, 128, 3604-3604.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59.	2.8	3
200	The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection. <i>Bone Marrow Transplantation</i> , 2017, 52, 902-904.	1.3	2
201	Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.	0.7	2
202	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146.	2.0	2
203	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357.	2.0	2
204	Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 993-995.	0.6	2
205	Chronic graft-versus-host disease in pancreas after kidney transplant recipients – An unrecognized entity. <i>American Journal of Transplantation</i> , 2021, 21, 883-888.	2.6	2
206	<scp>Pseudo-Volkman</scp> contracture as a complication of chronic graft-versus-host disease. <i>Dermatologic Therapy</i> , 2021, 34, e14701.	0.8	2
207	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004, 104, 892-892.	0.6	2
208	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. <i>Blood</i> , 2015, 126, 736-736.	0.6	2
209	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011, 118, 1752-1752.	0.6	2
210	Clinical Features and Outcomes of Isolated Myeloid Sarcoma in the United States: Analysis Using a National Dataset. <i>Blood</i> , 2016, 128, 1618-1618.	0.6	2
211	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722.	0.6	2
212	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427.	0.6	2
213	Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 34-42.	1.2	1
214	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401.	2.0	1
215	Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 155-160.	0.6	1
216	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 1898-1907.	1.3	1

#	ARTICLE	IF	CITATIONS
217	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	1.2	1
218	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a "graft versus host"-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	1.3	1
219	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	0.8	1
220	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	1.3	1
221	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	0.6	1
222	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	0.6	1
223	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma.. Blood, 2004, 104, 2927-2927.	0.6	1
224	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	0.6	1
225	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	0.6	1
226	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. Blood, 2011, 118, 1759-1759.	0.6	1
227	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	0.6	1
228	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Blood, 2012, 120, 602-602.	0.6	1
229	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. Blood, 2013, 122, 1732-1732.	0.6	1
230	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. Blood, 2013, 122, 2821-2821.	0.6	1
231	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. Blood, 2013, 122, 4049-4049.	0.6	1
232	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 1923-1923.	0.6	1
233	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Blood, 2015, 126, 3210-3210.	0.6	1
234	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. Blood, 2016, 128, 4694-4694.	0.6	1

#	ARTICLE	IF	CITATIONS
235	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
236	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. <i>Blood</i> , 2005, 106, 1173-1173.	0.6	1
237	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010, 116, 4109-4109.	0.6	1
238	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2011, 118, 4152-4152.	0.6	1
239	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1476-1476.	0.6	1
240	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 3873-3873.	0.6	1
241	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2013, 122, 1334-1334.	0.6	1
242	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1
243	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	0.6	1
244	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368.	0.6	1
245	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
246	Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. <i>Blood Advances</i> , 2022, , .	2.5	1
247	Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 835-836.	0.6	0
248	The D-Index Does Not Predict Invasive Fungal Infection (IFI) Among Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
249	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016, 103, 409-415.	0.7	0
250	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.3	0
251	Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 508-510.	1.3	0
252	Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 978-979.	1.3	0

#	ARTICLE	IF	CITATIONS
253	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 387-394.	0.5	0
254	Dâ€index as a marker of bloodstream infections in patients with allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13588.	0.7	0
255	Hemoglobinuria in the early post stem cell transplant period: Risk factors and association with outcomes. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0002262021.	0.9	0
256	Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004, 104, 5143-5143.	0.6	0
257	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 5420-5420.	0.6	0
258	Hematopathological Findings in Patients with Copper Deficiency and Hematologic Manifestations.. <i>Blood</i> , 2005, 106, 1680-1680.	0.6	0
259	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2005, 106, 5422-5422.	0.6	0
260	Implications of Body Weight Calculations for Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5445-5445.	0.6	0
261	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007, 110, 2995-2995.	0.6	0
262	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. <i>Journal of Clinical Oncology</i> , 2009, 27, 7039-7039.	0.8	0
263	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010, 116, 4518-4518.	0.6	0
264	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. <i>Blood</i> , 2010, 116, 3468-3468.	0.6	0
265	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010, 116, 3469-3469.	0.6	0
266	Impact of Rapid Lymphocyte and Monocyte Recovery on Overall Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine/Melphalan Conditioning. <i>Blood</i> , 2011, 118, 3040-3040.	0.6	0
267	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 600-600.	0.6	0
268	Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012, 120, 4804-4804.	0.6	0
269	Allogeneic Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. <i>Blood</i> , 2012, 120, 2850-2850.	0.6	0
270	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 4252-4252.	0.6	0



#	ARTICLE	IF	CITATIONS
271	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012, 120, 599-599.	0.6	0
272	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 1405-1405.	0.6	0
273	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 2145-2145.	0.6	0
274	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. <i>Blood</i> , 2013, 122, 2794-2794.	0.6	0
275	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. <i>Blood</i> , 2013, 122, 5472-5472.	0.6	0
276	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013, 122, 4048-4048.	0.6	0
277	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. <i>Blood</i> , 2013, 122, 4955-4955.	0.6	0
278	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 2098-2098.	0.6	0
279	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. <i>Blood</i> , 2013, 122, 5226-5226.	0.6	0
280	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2013, 122, 916-916.	0.6	0
281	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. <i>Blood</i> , 2013, 122, 3375-3375.	0.6	0
282	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. <i>Blood</i> , 2013, 122, 2081-2081.	0.6	0
283	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 5000-5000.	0.6	0
284	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	0.6	0
285	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260.	0.6	0
286	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015, 126, 4062-4062.	0.6	0
287	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4980-4980.	0.6	0
288	Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015, 126, 3154-3154.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	0.6	0
290	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	0.6	0
291	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. Blood, 2015, 126, 1401-1401.	0.6	0
292	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	0.6	0
293	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	0.6	0
294	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. Blood, 2015, 126, 5254-5254.	0.6	0
295	A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease. Blood, 2015, 126, 5532-5532.	0.6	0
296	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	0.6	0
297	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	0.6	0
298	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. Blood, 2016, 128, 1617-1617.	0.6	0
299	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. Blood, 2016, 128, 300-300.	0.6	0
300	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996.	0.6	0
301	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. Blood, 2016, 128, 4653-4653.	0.6	0
302	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 4593-4593.	0.6	0
303	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. Blood, 2016, 128, 510-510.	0.6	0
304	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	0.6	0
305	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. Blood, 2016, 128, 3599-3599.	0.6	0
306	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. <i>Blood</i> , 2018, 132, 2113-2113.	0.6	0
308	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2147-2147.	0.6	0
309	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	0.6	0
310	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018, 132, 4613-4613.	0.6	0
311	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. <i>Blood</i> , 2018, 132, 2678-2678.	0.6	0
312	Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas. <i>Blood</i> , 2018, 132, 3430-3430.	0.6	0
313	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689.	0.6	0
314	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0
315	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005.	0.6	0
316	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367.	0.6	0
317	Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. <i>Blood</i> , 2019, 134, 1222-1222.	0.6	0
318	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019, 134, 5441-5441.	0.6	0
319	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 4500-4500.	0.6	0
320	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019, 134, 5406-5406.	0.6	0
321	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. <i>Blood</i> , 2019, 134, 3300-3300.	0.6	0
322	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	0.6	0
323	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013.	0.6	0
324	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021, 138, 1267-1267.	0.6	0

#	ARTICLE	IF	CITATIONS
325	A novel Iowaâ€“Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal, 2021, 11, 183.	2.8	0
326	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. Blood, 2021, 138, 3900-3900.	0.6	0
327	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). Blood, 2021, 138, 1096-1096.	0.6	0
328	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. Blood, 2021, 138, 3956-3956.	0.6	0
329	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. Blood, 2021, 138, 3377-3377.	0.6	0
330	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-21.	0.6	0
331	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged â‰¥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0
332	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
333	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. Blood, 2020, 136, 43-44.	0.6	0
334	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0
335	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0
336	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	0.6	0
337	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	0.6	0
338	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0